![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer … Read the full press release